Anixa Historical Income Statement

ANIX Stock

USD 3.30 0.01 0.30%

Historical analysis of Anixa Biosciences income statement accounts such as Selling General Administrative of 4.2 M, Total Revenue of 229.4 K or Gross Profit of 53.5 K can show how well Anixa Biosciences performed in making a profits. Evaluating Anixa Biosciences income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Anixa Biosciences's future profits or losses.

Cash Flow Balance Sheet Income Statement

Oil Shock

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Anixa Biosciences latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Anixa Biosciences is a good buy for the upcoming year.

Net Income Gross Profit

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Anixa Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy Anixa Stock please use our How to Invest in Anixa Biosciences guide.

About Anixa Income Statement Analysis

Anixa Biosciences Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Anixa Biosciences shareholders. The income statement also shows Anixa investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Anixa Biosciences Income Statement Chart

At this time, Anixa Biosciences' Interest Expense is fairly stable compared to the past year. Total Other Income Expense Net is likely to rise to about 1 M in 2024, whereas Selling General Administrative is likely to drop slightly above 4.2 M in 2024.

Selling General Administrative Other Operating Expenses Ebitda Total Operating Expenses Income Before Tax Tax Provision

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Anixa Biosciences. It is also known as Anixa Biosciences overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Income Before Tax

Income Before Tax which can also be referred as pre-tax income is reported on Anixa Biosciences income statement and is an important metric when analyzing Anixa Biosciences profitability. Accounting techniques because taxes can be complex, and not perfectly consistent from one company to company, an analyst may use pre-tax income as a more stable measure of profitability.

Tax Provision

The amount set aside by a company to cover any estimated taxes for the current period. It reflects the company's expected tax liabilities.

Most accounts from Anixa Biosciences' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Anixa Biosciences current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Anixa Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy Anixa Stock please use our How to Invest in Anixa Biosciences guide.At this time, Anixa Biosciences' Interest Expense is fairly stable compared to the past year. Total Other Income Expense Net is likely to rise to about 1 M in 2024, whereas Selling General Administrative is likely to drop slightly above 4.2 M in 2024.

Anixa Biosciences income statement Correlations

	Interest Expense	Selling General Administrative	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Ebitda	Total Operating Expenses	Net Income	Income Tax Expense	Depreciation And Amortization	Income Before Tax	Total Other Income Expense Net	Research Development	Cost Of Revenue	Net Income From Continuing Ops	Non Operating Income Net Other	Non Recurring	Interest Income	Minority Interest	Net Interest Income	Reconciled Depreciation
Interest Expense		0.21	-0.13	-0.13	-0.23	0.38	0.38	0.38	-0.34	0.12	0.51	0.04	0.11	-0.63	-0.69	0.41	0.21	-0.61	0.22	0.0	-0.38	-0.39	0.37
Selling General Administrative	0.21		0.26	0.26	0.85	-0.65	-0.65	-0.65	0.81	-0.73	-0.19	-0.08	-0.74	-0.19	0.44	0.18	-0.62	-0.22	0.24	0.04	0.3	0.28	-0.35
Total Revenue	-0.13	0.26		1.0	0.33	-0.36	-0.37	-0.38	0.37	-0.34	-0.26	-0.19	-0.34	0.05	0.39	-0.14	-0.36	0.05	-0.04	-0.18	-0.08	0.03	-0.34
Gross Profit	-0.13	0.26	1.0		0.33	-0.36	-0.37	-0.38	0.37	-0.34	-0.26	-0.19	-0.34	0.05	0.39	-0.14	-0.36	0.06	-0.05	-0.18	-0.08	0.03	-0.34
Other Operating Expenses	-0.23	0.85	0.33	0.33		-0.8	-0.79	-0.78	0.97	-0.78	-0.52	0.09	-0.79	0.0	0.74	0.15	-0.66	-0.01	0.32	-0.06	0.39	0.4	-0.43
Operating Income	0.38	-0.65	-0.36	-0.36	-0.8		1.0	1.0	-0.91	0.94	0.48	0.02	0.94	-0.2	-0.89	0.42	0.89	-0.15	0.2	0.06	-0.5	-0.54	0.55
Ebit	0.38	-0.65	-0.37	-0.37	-0.79	1.0		1.0	-0.9	0.94	0.5	0.04	0.94	-0.22	-0.88	0.43	0.88	-0.15	0.22	0.04	-0.53	-0.55	0.58
Ebitda	0.38	-0.65	-0.38	-0.38	-0.78	1.0	1.0		-0.9	0.93	0.5	0.09	0.94	-0.23	-0.88	0.45	0.88	-0.15	0.24	0.02	-0.55	-0.57	0.61
Total Operating Expenses	-0.34	0.81	0.37	0.37	0.97	-0.91	-0.9	-0.9		-0.85	-0.54	0.03	-0.86	0.12	0.85	-0.11	-0.76	0.09	0.07	-0.07	0.45	0.47	-0.5
Net Income	0.12	-0.73	-0.34	-0.34	-0.78	0.94	0.94	0.93	-0.85		0.31	-0.03	1.0	0.12	-0.76	0.29	0.93	0.15	0.11	0.11	-0.38	-0.4	0.42
Income Tax Expense	0.51	-0.19	-0.26	-0.26	-0.52	0.48	0.5	0.5	-0.54	0.31		0.06	0.33	-0.48	-0.49	0.07	0.09	-0.42	-0.11	-0.11	-0.53	-0.52	0.56
Depreciation And Amortization	0.04	-0.08	-0.19	-0.19	0.09	0.02	0.04	0.09	0.03	-0.03	0.06		-0.02	-0.22	-0.02	0.23	0.03	-0.01	0.26	-0.42	-0.37	-0.25	0.62
Income Before Tax	0.11	-0.74	-0.34	-0.34	-0.79	0.94	0.94	0.94	-0.86	1.0	0.33	-0.02		0.11	-0.76	0.28	0.93	0.15	0.1	0.11	-0.38	-0.4	0.43
Total Other Income Expense Net	-0.63	-0.19	0.05	0.05	0.0	-0.2	-0.22	-0.23	0.12	0.12	-0.48	-0.22	0.11		0.31	-0.47	0.1	0.89	-0.36	0.31	0.48	0.53	-0.46
Research Development	-0.69	0.44	0.39	0.39	0.74	-0.89	-0.88	-0.88	0.85	-0.76	-0.49	-0.02	-0.76	0.31		-0.41	-0.81	0.24	-0.17	-0.03	0.52	0.56	-0.56
Cost Of Revenue	0.41	0.18	-0.14	-0.14	0.15	0.42	0.43	0.45	-0.11	0.29	0.07	0.23	0.28	-0.47	-0.41		0.39	-0.41	0.95	-0.01	-0.26	-0.28	0.28
Net Income From Continuing Ops	0.21	-0.62	-0.36	-0.36	-0.66	0.89	0.88	0.88	-0.76	0.93	0.09	0.03	0.93	0.1	-0.81	0.39		0.15	0.22	0.11	-0.35	-0.36	0.4
Non Operating Income Net Other	-0.61	-0.22	0.05	0.06	-0.01	-0.15	-0.15	-0.15	0.09	0.15	-0.42	-0.01	0.15	0.89	0.24	-0.41	0.15		-0.35	-0.09	0.16	0.17	-0.15
Non Recurring	0.22	0.24	-0.04	-0.05	0.32	0.2	0.22	0.24	0.07	0.11	-0.11	0.26	0.1	-0.36	-0.17	0.95	0.22	-0.35		0.06	-0.09	-0.05	0.09
Interest Income	0.0	0.04	-0.18	-0.18	-0.06	0.06	0.04	0.02	-0.07	0.11	-0.11	-0.42	0.11	0.31	-0.03	-0.01	0.11	-0.09	0.06		0.58	0.75	-0.46
Minority Interest	-0.38	0.3	-0.08	-0.08	0.39	-0.5	-0.53	-0.55	0.45	-0.38	-0.53	-0.37	-0.38	0.48	0.52	-0.26	-0.35	0.16	-0.09	0.58		0.85	-0.84
Net Interest Income	-0.39	0.28	0.03	0.03	0.4	-0.54	-0.55	-0.57	0.47	-0.4	-0.52	-0.25	-0.4	0.53	0.56	-0.28	-0.36	0.17	-0.05	0.75	0.85		-0.76
Reconciled Depreciation	0.37	-0.35	-0.34	-0.34	-0.43	0.55	0.58	0.61	-0.5	0.42	0.56	0.62	0.43	-0.46	-0.56	0.28	0.4	-0.15	0.09	-0.46	-0.84	-0.76

Click cells to compare fundamentals

Anixa Biosciences Account Relationship Matchups

Anixa Biosciences income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Selling General Administrative	5.6M	7.1M	7.2M	6.3M	7.2M	4.2M
Total Revenue	0.0	512.5K	2.5B	210K	241.5K	229.4K
Gross Profit	(90.2K)	127.5K	2.5B	49K	56.4K	53.5K
Other Operating Expenses	10.0M	13.6M	13.9M	11.2M	12.9M	6.9M
Operating Income	(10.0M)	(13.1M)	(13.9M)	(11.0M)	(9.9M)	(9.4M)
Ebit	(10.1M)	(13.1M)	(13.8M)	(11.0M)	(9.9M)	(9.4M)
Ebitda	(10.0M)	(13.1M)	(13.7M)	(11.0M)	(9.9M)	(9.4M)
Total Operating Expenses	10.0M	13.3M	13.9M	11.1M	12.7M	6.6M
Net Income	(10.1M)	(12.9M)	(13.5M)	(9.8M)	(8.8M)	(9.3M)
Income Tax Expense	40.2K	(181.3K)	(280K)	(119K)	(136.9K)	(130.0K)
Depreciation And Amortization	90.2K	59.9K	42K	46K	52.9K	50.3K
Income Before Tax	(10.1M)	(13.1M)	(13.8M)	(9.9M)	(8.9M)	(9.4M)
Total Other Income Expense Net	(114.2K)	7.7K	104K	1.1M	972.9K	1.0M
Research Development	4.4M	6.2M	6.7M	4.8M	5.5M	3.6M
Cost Of Revenue	90.2K	385.0K	42K	161K	185.2K	175.9K
Net Income From Continuing Ops	(9.9M)	(13.1M)	(13.8M)	(9.9M)	(8.9M)	(9.4M)
Non Operating Income Net Other	46.0K	71.4K	33.9K	104K	119.6K	125.6K
Net Income Applicable To Common Shares	(11.6M)	(10.0M)	(13.0M)	(13.6M)	(12.2M)	(12.8M)
Interest Income	33.9K	2.3K	104K	1.1M	1.2M	1.3M
Minority Interest	(74.0K)	173.5K	(176K)	119K	136.9K	143.7K
Net Interest Income	33.9K	2.3K	104K	1.1M	1.2M	1.3M
Reconciled Depreciation	90.2K	59.9K	42K	46K	41.4K	39.3K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for Anixa Stock Analysis

When running Anixa Biosciences' price analysis, check to measure Anixa Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Anixa Biosciences is operating at the current time. Most of Anixa Biosciences' value examination focuses on studying past and present price action to predict the probability of Anixa Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Anixa Biosciences' price. Additionally, you may evaluate how the addition of Anixa Biosciences to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Anixa Historical Income Statement

About Anixa Income Statement Analysis

Anixa Biosciences Income Statement Chart

Other Operating Expenses

Total Operating Expenses

Income Before Tax

Tax Provision

Anixa Biosciences income statement Correlations

Anixa Biosciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Anixa Biosciences income statement Accounts

Also Currently Popular

Additional Tools for Anixa Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Gross Profit	+ 1.0	Total Revenue
Ebit	+ 1.0	Operating Income
Ebitda	+ 1.0	Operating Income
Ebitda	+ 1.0	Ebit
Income Before Tax	+ 1.0	Net Income
Total Operating Expenses	+ 0.97	Other Operating Expenses

Total Operating Expenses	- 0.91	Operating Income
Total Operating Expenses	- 0.9	Ebitda
Total Operating Expenses	- 0.9	Ebit
Research Development	- 0.89	Operating Income
Research Development	- 0.88	Ebitda
Research Development	- 0.88	Ebit